Local Institution

Dijon 21079

0 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome (ACS), Advanced Cutaneous Melanoma, Alzheimer's Disease, Breast Cancer, Diabetic Peripheral Neuropathic Pain, Melanoma, Metastases, Metastasis, Non-Squamous Cell Non-small Cell Lung Cancer, Pulmonary Embolism, Rheumatoid Arthritis, Squamous Cell Non-small Cell Lung Cancer

Studies at this site

• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC — Completed
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) — Completed
• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma — Completed
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants — Withdrawn before enrolling
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) — Completed
• Safety Study of Apixaban in Recent Acute Coronary Syndrome — Completed
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Diabetic Peripheral Neuropathic Pain (DPNP) — Completed
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer — Completed
• Remission and Joint Damage Progression in Early Rheumatoid Arthritis — Completed